Showing results (121-130 of 153) with videos related to

Sort By:
Pageof 16
European Journal of Cancer & Clinical Oncology|July 1, 1989
Diagnostic value of mucin-like carcinoma-associated antigen (MCA) in breast cancerS Rasoul-Rockenschaub, C C Zielinski, E Kubista, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2013
Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN)C Obasaju, L Bowman, P Wang, et al.
Oncology|April 15, 1999
Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancerM Raderer, M H Hejna, J B Valencak, et al.
European Journal of Cancer (Oxford, England : 1990)|July 7, 2014
Pulmonary metastasectomy for soft tissue sarcoma--report from a dual institution experience at the Medical University of ViennaS Schur, K Hoetzenecker, W Lamm, et al.
Clinical & Experimental Metastasis|November 14, 2018
Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care centerL M Füreder, G Widhalm, B Gatterbauer, et al.
British Journal of Cancer|June 1, 1995
Reduced mitogenic stimulation of peripheral blood mononuclear cells as a prognostic parameter for the course of breast cancer: a prospective longitudinal studyC Wiltschke, M Krainer, A C Budinsky, et al.
European Cytokine Network|October 7, 2000
Relation of pro- and anti-inflammatory cytokines and the production of nitric oxide in patients receiving high-dose immunotherapy with interleukin-2G J Locker, J Kofler, B Stoiser, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2008
Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agentG Carteni, C Manegold, G Martin Garcia, et al.
European Journal of Cancer (Oxford, England : 1990)|October 19, 2005
Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experienceG G Steger, R Bartsch, C Wenzel, et al.
European Journal of Cancer (Oxford, England : 1990)|May 30, 2012
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancerI Lang, M J Inbar, Z Kahán, et al.
Pageof 16